All Oncology articles
-
NewsATRX mutations reprogram chromatin to drive glioma progression
Scientists at MD Anderson Cancer Center have revealed how ATRX mutations restructure chromatin and activate oncogenic developmental pathways in glioma, pointing towards novel therapeutic targets including the HOXA signalling axis.
-
NewsMETTL3 protein finds new mechanism driving breast cancer metastasis
Scientists at Umeå University have uncovered a previously unknown function for the RNA-modifying protein METTL3, revealing it plays a distinct role in enabling breast cancer cells to invade surrounding tissue and form metastases – findings that could open new avenues for therapeutic targeting.
-
NewsHidden vulnerability in persister cells could prevent KRAS cancer relapse
Scientists at Chiba University have identified a metabolic vulnerability in drug-tolerant cancer cells that survive KRAS-targeted therapy, opening a potential route to combination treatments designed to prevent disease recurrence in lung, pancreatic and colorectal cancers.
-
NewsResearchers reveal how entinostat disrupts pancreatic cancer repair
Scientists at the Salk Institute have discovered how the investigational HDAC inhibitor entinostat disrupts DNA repair mechanisms in pancreatic cancer cells, potentially enabling more effective combination therapies with reduced toxicity through novel nanoparticle delivery systems.
-
NewsmRNA vaccine shows promise against childhood neuroblastoma cancer
Preclinical study demonstrates effectiveness of experimental mRNA vaccine against neuroblastoma, reducing tumour size by 70 percent and delaying development. RCSI researchers used peptide nanoparticles targeting GPC2 protein to direct immune response against cancer cells, offering potential new treatment approach for aggressive childhood malignancy.
-
NewsBlocking cathepsin B protein enhances CAR T-cell therapy effectiveness
University of Maryland researchers have discovered that blocking cathepsin B protein prevents CAR T-cells from losing effectiveness, potentially improving long-term outcomes for blood cancer patients. The preclinical findings reveal that engineered immune cells inadvertently weaken themselves by acquiring tumour fragments, a process that can be prevented through targeted protein inhibition.
-
NewsLabGenius and LG Chem partner on AI-driven cancer antibodies
LabGenius Therapeutics has partnered with LG Chem to develop next-generation multispecific antibodies targeting solid tumours. The collaboration combines AI-driven drug discovery with oncology development expertise to identify therapeutics with improved selectivity and reduced toxicity.
-
NewsNew framework standardises glioma organoid research for translational studies
A collaborative review published in Neuro-Oncology establishes a unified classification system for glioma organoid models, addressing inconsistent terminology and methodology across the rapidly expanding field.
-
ReportContext is everything: how spatial biology is changing our understanding of disease
Studying individual cells has revolutionised biomedical research, but it doesn’t tell the whole story. Discover how spatial biology is revealing disease mechanisms with implications for biomarkers, immunotherapy and drug development.
-
ArticleFlow-based human tumour models reveal immune responses missed by static culture
Static cultures can miss critical immune–tumour interactions. Learn how the Mera™ flow-based human tissue model better captures T-cell activity to strengthen preclinical immunotherapy research.
-
NewsCytokine-armoured CAR T cells target glioblastoma while reducing treatment toxicity
UCLA Health researchers have developed cytokine-armoured CAR T cells that directly attack glioblastoma tumours whilst recruiting the body’s wider immune system. The engineered cells showed improved tumour control in mouse models and could address antigen heterogeneity challenges that have limited CAR T therapy success in solid tumours.
-
ArticleAACR 2026 part two: integrating AI, spatial biology and next-gen therapeutics
In part two of our AACR 2026 coverage, industry leaders were focussed on how the field is no longer constrained by data generation or molecular design, but by the challenge of connecting systems, standardising workflows and ensuring biological insights.
-
NewsRadiotherapy boosts CAR T cell survival in solid tumours
Mount Sinai researchers have discovered that focused irradiation significantly enhances CAR T cell therapy effectiveness in solid tumours by promoting dendritic cell-mediated antigen presentation, enabling sustained immune cell expansion within the tumour microenvironment whilst minimising off-target toxicity.
-
NewsNotch2 enables breast cancer dormancy in protective bone marrow niches
New research has demonstrated how breast cancer cells exploit protective bone marrow niches to remain dormant for years, identifying Notch2 signalling and stem cell-like markers as key regulators of cellular dormancy that could inform therapeutic strategies to prevent relapse.
-
NewsFerroptosis emerges as strategy against treatment-resistant digestive cancers
Researchers are investigating ferroptosis, an iron-dependent cell death pathway, as a potential approach to overcome treatment resistance in digestive cancers.
-
NewsGene-based CIN score predicts breast cancer survival and immunotherapy response
A 13-gene chromosomal instability scoring system developed by Shanghai researchers correlates with survival outcomes and immunotherapy response in breast cancer patients.
-
NewsPlatinum-antibody conjugates enhance immunotherapy while reducing chemotherapy toxicity
A novel platinum(IV)-antibody conjugate platform delivers low-dose chemotherapy directly to tumours, upregulating MHC-I expression and enhancing anti-PD-1 responses while minimising systemic exposure. The approach addresses immune evasion mechanisms that limit checkpoint inhibitor efficacy.
-
NewsMetabolic vulnerabilities identified in rare Fibrolamellar liver cancer
Researchers have identified metabolic vulnerabilities in Fibrolamellar cancer, a rare liver malignancy affecting adolescents and young adults, using functional profiling and mass spectrometry. The findings suggest chemotherapy-resistant tumours may be susceptible to metabolism-targeted therapies.
-
NewsAI platform identifies novel gp130 inhibitor for colorectal cancer
An AI-assisted drug discovery platform using transfer learning has identified a promising gp130 inhibitor for colorectal cancer.
-
ArticleWhy AI models need patient data to deliver in drug discovery
Despite rapid advances in AI, many drug discovery models still struggle to translate computational predictions into clinical outcomes. Thomas Clozel explains how Owkin is training AI on large-scale patient-derived data while integrating experimental and clinical validation directly into model development.